LA TRIBUNE – Cancer : Onxeo vise une nouvelle stratégie thérapeutique pour “contenir l’évolution de la maladie”
Read the article in La Tribune (in French)
CLINICAL LEADER – The Science Of M&A: Making The Most Of Your Financial Resources
Read the article on clinicalleader.com
Onxeo launches a capital increase by means of an accelerated book-build offering
Paris (France), June 19, 2017 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the […]
Onxeo successfully raises €15 Million with US and European investors
Offering upsized in response to investor demand Paris (France), June 20, 2017 – 08:00 am CEST – Onxeo S.A. […]
Onxeo Announces Positive Preclinical Proof of Concept Results Confirming AsiDNA™ Activity via Systemic Administration
Strong data confirms near-term plan to initiate clinical trial for AsiDNA™, Onxeo’s breakthrough DNA Repair Inhibitor Paris (France), July 05 […]
Onxeo Reports First-Half 2017 Results and Business Update
Sound cash position of €27.7m as at June 30, 2017 and cash runway till Q1 2019 Development of the core […]
Onxeo Divests Two Non-Core Products in Oral Pathologies to Vectans Pharma
Transaction confirms Onxeo’s strategic focus on innovative orphan oncology drugs Paris (France), July 31, 2017 – 05:45 pm CEST – […]
Onxeo Grants Exclusive Worldwide License of Validive® developed for the treatment of oral severe mucositis to Monopar Therapeutics
Agreement includes substantial milestone payments up to $108m as well as escalating royalties on future sales Monopar Therapeutics will drive […]
Onxeo to host a Conference Call today to comment on the main findings from ReLive Phase III Study of Livatag®
Paris (France), September 18, 2017 – 8:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the […]
Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat
Results demonstrate a very strong synergistic effect between AsiDNA™, first-in-class DNA break repair inhibitor (DBRi), and histone deacetylase inhibitors (HDACi) […]
Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides
2 OCT., 2017 PlatON™ will generate new best-in-class DNA-targeting drug candidates starting in 2018 In parallel, the Company advances its […]
Onxeo Reports First Instance Decision from the Commercial Court of Paris in the Lawsuit against SpeBio/SpePharm
Paris (France), October 17, 2017 – 10 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]
Onxeo Announces Top-Line Results from ReLive Phase III Study of Livatag® in Advanced Hepatocellular Carcinoma
Paris (France), September 11, 2017 – 8:00 pm CEST– Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), […]
Onxeo to attend Key Investor and Partnering Conferences in H1 2018
Paris (France), January 3, 2018 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]
Onxeo Completes Enrollment in Phase III Study of Livatag® for the Treatment of Hepatocellular Carcinoma
Milestone completion in line with expected preliminary outcomes mid-2017 Paris (France), Copenhagen (Denmark), January 24, 2017 – 18:30 CET – […]
Onxeo receives the EnterNext Tech 40 Label
Onxeo is admitted to the “Tech 40” index, which incorporates 40 outstanding small and midcap Tech companies listed on the […]
Onxeo Establishes Scientific Advisory Board with International Experts in DNA-targeting
Professor Tomas Lindahl, DNA Repair Pioneer and 2015 Nobel Prize laureate, will serve as Chair of the Scientific Advisory Board […]
Combined General Meeting on April 26, 2017
Paris (France), April 5, 2017 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company […]
Annual General Meeting of April 26, 2017
All ordinary resolutions approved Two new independent directors appointed Renewal of the terms of office of Mrs Judith Greciet, CEO, […]
Publication of 2016 Registration Document
Paris (France), April 25, 2017 – 5.45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company […]
Radiotherapy, immunotherapy and DNA repair inhibitors: a winning combination towards the oncology of the future
The Institut Curie and Onxeo join forces in this ambitious project that will benefit cancer patients Paris (France), Copenhagen (Denmark), […]
Information on ReLive Trial Design and Role of its Data Safety and Monitoring Board
Paris (France), February 8, 2017 – 8.30 am CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a clinical-stage biotechnology […]
Onxeo receives USPTO Notice of Allowance for a new AsiDNA™-related patent, expanding its IP protection in the U.S.
New patent expands Onxeo’s intellectual property to a large family of compounds related to AsiDNA™ Paris (France), February 13, 2017 […]
Onxeo Appoints Seasoned Executives to Accelerate Preclinical and Clinical Development
Françoise Bono, PhD, Named Chief Scientific Officer to Lead Preclinical Activities Olivier de Beaumont, MD, MBA, Appointed Chief Medical Officer […]
Full-year 2016 Results and Outlook for 2017
Reinforcement of Onxeo’s strategic positioning in the development of innovative oncology treatments Acquisition of DNA Therapeutics and the AsiDNATM product, […]
Onxeo to Present Data Supporting Three Key Orphan Oncology Assets at AACR Annual Meeting
Preclinical studies of AsiDNA™, Livatag® and Beleodaq® Paris (France), March 21, 2017 – 6 pm CET – Onxeo S.A. (Euronext […]
Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL)
Paris, April 24, 2017 – 18 :30 CEST. Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Idis Managed Access (MA) […]
Onxeo: Q1 2017 financial information and business update
Revenues up 55% to €1.2 million Cash position of €21.7 million at March 31, 2017 All strategic […]
Onxeo announces allowance of U.S. patent for Livatag® in hepatocellular carcinoma
USPTO Notice of Allowance received for patent related to specific route of administration for Livatag® provides protection of related claims […]
Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC
Paris (France), May 23, 2017 – 6.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology […]
Onxeo Provides Strategy Update and Reports 2017 Third Quarter Financial Information
Company completes strategic shift to innovative DNA-targeting programs and platON™ chemistry platform of decoy oligonucleotides Development of lead product AsiDNA™ […]